IRIS
BRILLANTI, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.918
EU - Europa 3.224
AS - Asia 2.223
SA - Sud America 471
AF - Africa 164
OC - Oceania 5
AN - Antartide 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 11.007
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.833
GB - Regno Unito 734
SG - Singapore 688
RU - Federazione Russa 668
CN - Cina 614
IE - Irlanda 531
IT - Italia 445
BR - Brasile 398
FR - Francia 299
KR - Corea 280
VN - Vietnam 210
HK - Hong Kong 209
UA - Ucraina 144
SE - Svezia 121
ZA - Sudafrica 90
DE - Germania 85
FI - Finlandia 85
CA - Canada 42
IN - India 41
NG - Nigeria 32
AR - Argentina 29
TR - Turchia 29
MX - Messico 27
BD - Bangladesh 23
JP - Giappone 22
IQ - Iraq 19
NL - Olanda 19
ES - Italia 17
BE - Belgio 14
AT - Austria 13
EC - Ecuador 13
EG - Egitto 13
ID - Indonesia 12
IR - Iran 11
KE - Kenya 11
PL - Polonia 10
CL - Cile 9
PK - Pakistan 9
CO - Colombia 8
UZ - Uzbekistan 8
PT - Portogallo 7
CH - Svizzera 6
NP - Nepal 6
PE - Perù 6
SA - Arabia Saudita 6
MA - Marocco 5
AU - Australia 4
DZ - Algeria 4
HN - Honduras 4
JM - Giamaica 4
LB - Libano 4
LT - Lituania 4
MY - Malesia 4
PH - Filippine 4
PY - Paraguay 4
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
GE - Georgia 3
GR - Grecia 3
JO - Giordania 3
KZ - Kazakistan 3
RO - Romania 3
TN - Tunisia 3
AE - Emirati Arabi Uniti 2
AO - Angola 2
AZ - Azerbaigian 2
BO - Bolivia 2
CR - Costa Rica 2
HR - Croazia 2
LV - Lettonia 2
OM - Oman 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
VE - Venezuela 2
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CI - Costa d'Avorio 1
DK - Danimarca 1
ET - Etiopia 1
GS - Georgia del Sud e Isole Sandwich Australi 1
KG - Kirghizistan 1
KI - Kiribati 1
LU - Lussemburgo 1
MO - Macao, regione amministrativa speciale della Cina 1
PA - Panama 1
RS - Serbia 1
SI - Slovenia 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TG - Togo 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 11.007
Salva come PNG Salva come JPEG
Città #
Southend 638
Dallas 583
Fairfield 583
Dublin 525
Ashburn 404
Singapore 349
Chandler 324
Woodbridge 269
Santa Clara 246
Seattle 233
Hong Kong 204
Wilmington 203
Cambridge 200
Beijing 180
Houston 176
Jacksonville 175
Bupyeong-gu 167
Moscow 161
Princeton 132
San Jose 119
Ann Arbor 107
Johannesburg 87
Helsinki 77
Siena 77
The Dalles 73
Lauterbourg 70
Ho Chi Minh City 68
Hefei 64
Seoul 60
Los Angeles 55
Nanjing 51
Milan 43
São Paulo 40
Council Bluffs 36
Hanoi 36
San Diego 36
San Mateo 36
Gimpo-si 35
New York 34
Abuja 31
London 30
Paris 29
Shanghai 26
Boardman 25
Redondo Beach 25
Rome 25
Florence 23
Buffalo 21
Columbus 21
Tokyo 19
Dong Ket 18
Dearborn 17
Izmir 17
Brasília 15
Frankfurt am Main 15
Hebei 15
Bari 14
Gwangyang-si 14
Brooklyn 12
Brussels 12
Nuremberg 12
Phoenix 12
Shenyang 12
Bologna 11
Chennai 11
Orem 11
Toronto 11
Bengaluru 10
Da Nang 10
Munich 10
Rio de Janeiro 10
San Francisco 10
Warsaw 10
Belo Horizonte 9
Cupramontana 9
Nanchang 9
Naples 9
Palermo 9
Turin 9
Catania 8
Jiaxing 8
Poplar 8
Tianjin 8
Vienna 8
Amsterdam 7
Ascoli Piceno 7
Cairo 7
Changsha 7
Chicago 7
Curitiba 7
Mexico City 7
Montegranaro 7
Montreal 7
Norwalk 7
Prato 7
Atlanta 6
Baghdad 6
Biên Hòa 6
Can Tho 6
Guayaquil 6
Totale 7.721
Salva come PNG Salva come JPEG
Nome #
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals 512
Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals 253
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 251
Direct antiviral therapy for hepatitis C and hepatocellular carcinoma: facing the conundrum 246
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 241
Distribution of three major hepatitis C virus genotypes in Italy. A multicentre study of 49 5 patients with chronic hepatitis C 235
Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis 230
Western Experience of Hepatolithiasis: Clinical Insights from a Case Series in a Tertiary Center 222
Hepatitis C viraemia rebound after “successful” interferon therapy in patients with chronic non‐A, non‐B hepatitis 221
Screening and detecting significant liver fibrosis in patients with NAFLD: A practical approach using non-invasive tests 209
A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C 200
Primary Biliary cholangitis case-finding: an italian multicenter observational study on patients with incidental finding of anti-mithocondrial antibodies 194
Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older 194
Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients 193
HCV INFECTION AND CHRONIC ACTIVE HEPATITIS IN ALCOHOLICS 184
HEPATITIS-C VIRUS - A POSSIBLE CAUSE OF CHRONIC HEPATITIS IN ALCOHOLICS 181
Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C 180
A multimedia multilanguage web-based platform can assess and increase the awareness on HCV infection of Pakistani people living in Italy 179
Effect of α‐interferon therapy on hepatitis C viraemia in community‐acquired chronic non‐A, non‐B hepatitis: A quantitative polymerase chain reaction study 175
Serum pepsinogen I and II concentrations and IgG antibody to Helicobacter pylori in dyspeptic patients 174
Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience 173
Incidental findings of anti-mitochondrial antibodies without evidence of Primary Biliary Cholangitis. 170
Aberrant fragile histidine triad gene transcripts in primary hepatocellular carcinoma and liver cirrhosis 164
EFFECT OF LACTOBACILLUS ACIDOPHILUS AND BIFIDOBACTERIUM BIFIDUM ON RECTAL CELL-KINETICS AND FECAL PH 161
Cell renewal and cancer risk of the stomach: Analysis of cell proliferation kinetics in atrophic gastritis 160
Comment on “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: causality or casualty?” 160
Incidental finding of anti-mitochondrial antibody: a neglected entity needing reappraisal 159
Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study 159
Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation 157
Proctosigmoidite ulcerosa refrattaria e recidivante alla terapia topica trattata con beclometasone dipropionato orale 157
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis 154
The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes 152
Evaluation of Drug Interactions in Patients Treated with DAAs for Hepatitis C Therapy with Comorbidities and Cardiovascular Issues—A Delphi Consensus Project 150
Peginterferon-based therapy for chronic hepatitis C virus infection in patients with normal alanine aminotransferase levels 149
Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? 146
Ribavirin for chronic hepatitis C: And the mystery goes on 145
Serum IgM antibodies to hepatitis C virus in acute and chronic hepatitis C 144
Persistent hepatitis C viraemia without liver disease 142
Reactivation of Crohn's disease after pandemic aH1N1 and seasonal flu vaccinations 141
LONG-TERM PERSISTENCE OF IGM ANTIBODIES TO HCV IN CHRONIC HEPATITIS-C 140
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3 139
Treatment with direct acting antiviral agents-based regimen in HCV patients with advanced liver disease: Analysis of an Italian multicenter observational study 138
Significance of IgM antibody to hepatitis C virus in patients with chronic hepatitis C 137
Serological and histological aspects of hepatitis C virus infection in alcoholic patients 135
Spleen stiffness measurements predict the risk of hepatic decompensation after direct-acting antivirals in HCV cirrhotic patients 133
Role of amantadine and other adjuvant therapies in the treatment of hepatitis C 131
Direct acting antivirals for the treatment of elderly patients with HCV advanced disease in the real life practice 131
Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic-HCV patients 130
Severe acute autoimmune hepatitis after natalizumab treatment 128
What hides behind an intention-to-treat analysis? 128
Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C 120
Enhanced response to peginterferon-alpha-2a based triple therapy in previously non-responsive chronic hepatitis C: Final results of PRETTY study 116
Antibodies against pegylated interferon-alpha affect response to treatment in patients with chronic hepatitis C 115
Management of Delta Hepatitis 45 years after the discovery of HDV 114
Liver Stiffness Values to Predict Occurrence and Recurrence of Hepatocellular Carcinoma 113
Reversibility of gastrointestinal motor abnormalities in chronic intestinal pseudo-obstruction 110
DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN HCV CIRRHOTIC PATIENTS TREATED WITH DIRECT ACTING ANTIVIRALS 109
Re-treatment of patients with chronic hepatitis C in clinical practice: Results of a multicenter retrospective survey [Ritrattamento dei pazienti con epatite cronica da HCV nella pratica clinica: Risultati di uno studio multicentrico retrospettivo] 98
Prospective study on the prevalence of HCV infection in consecutive adult inpatients in a hospital division of Internal Medicine in Tuscany 95
Whipple's disease with melaena and multiple petechial haemorrhages in duodenal mucosa 94
RECTAL CELL-PROLIFERATION AND COLON CANCER RISK IN ULCERATIVE-COLITIS 91
Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders 91
Trattamento della Epatite da HCV 85
Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: Predictive role in HCC development in cirrhotic patients 85
Three-year follow-up of chronic hepatitis C patients treated with ribavirin plus interferon-alfa combination therapy: Evidence for long-term efficacy and safety 82
Prospective evaluation of aberrant p16 methylation in serum of patients before and after therapy for localized HCC 77
The role of gut microbiota in chronic liver diseases 76
Imaging Features of Microvascular Invasion in Hepatocellular Carcinoma Developed in HCV-Related Cirrhosis after Direct-Acting Antiviral Therapy 76
Loss and seroconversion of hepatitis B surface antigen after vaccine therapy in chronic hepatitis B patients treated with nucleoside/nucleotide analogues 75
THU-490 - Spleen stiffness measurement: a useful prognostic tool in HCV patients treated with DAAs regimens 73
Spleen stiffness measurement: A useful prognostic tool in HCV patients treated with DAAs regimens 70
La ribavirina nell'epatite cronica C: storia e segreti di un grande successo 67
THU-492 - Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: predictive role in hepatocellular carcinoma development in in cirrhotic patients 67
VIROLOGICAL FAILURES TO NEW DIRECT ACTING ANTIVIRALS IN A REAL LIFE SETTING MAY REQUIRE UNCONVENTIONAL REGIMENS FOR RE-TREATMENT 63
Terapia cellulare in Epatologia 58
RIBAVIRIN PRIMING ENHANCES EFFICACY OF CHRONIC HEPATITIS C RE-TREATMENT IN PATIENTS WHO HAD NOT RESPONDED TO PREVIOUS COMBINATION THERAPY 57
Panel discussion 55
null 10
Totale 11.229
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.955
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.955
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021223 0 0 0 0 0 0 0 0 0 107 46 70
2021/2022750 45 68 44 54 28 26 37 37 41 78 92 200
2022/20231.021 89 90 124 158 90 237 10 78 83 4 32 26
2023/2024910 63 57 94 103 43 187 232 17 6 33 16 59
2024/20251.628 52 85 166 68 171 112 17 110 135 129 178 405
2025/20263.805 273 552 480 553 594 170 406 166 296 315 0 0
Totale 11.229